Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system

Stefania Croci, Christian V. Recktenwald, Rudolf Lichtenfels, Giordano Nicoletti, Sven P. Dressler, Carla De Giovanni, Annalisa Astolfi, Arianna Palladini, Kazuo Shin-Ya, Lorena Landuzzi, Patrizia Nanni, Pier Luigi Lollini, Barbara Seliger

Research output: Contribution to journalArticle

Abstract

The prevention of mammary carcinoma by immunological strategies targeting the HER-2/neu receptor has proved to be effective in preclinical models. Thus, a well-characterized HER-2/neu oncogene-driven mammary carcinogenesis model was analysed by various profiling strategies following "triplex" vaccination to identify new candidate targets for breast cancer immunoprevention. 2-DE-based proteomic profiling of preneoplastic and tumour lesions versus normal and aged mammary tissue demonstrated that tumour progression was associated with an up-regulation of molecular chaperones including glucose-regulated protein (GRP)78 and of proteins favouring cell motility, which was in line with the corresponding transcriptomic profiling data. Furthermore, PROTEOMEX analyses suggested that naturally induced autoantibody responses occur during early phases of mammary cancer progression. Most of the cancer progression-induced antibodies targeted proteins of normal and preneoplastic mammary glands. However, three proteins were only recognized by sera obtained from vaccinated mice, including 2 isoforms of annexin A6. The distinct expression patterns for annexin A6 and GRP78 during tumour progression were further verified by western blot and/or immunoprecipitation. In addition, an inhibitor-mediated blockade of GRP78 expression in a model cell line caused a reduced cell growth. Thus, the proteome-based approaches applied in the murine BALB-NeuT model might indeed provide candidates for immunoprevention strategies in breast cancer.

Original languageEnglish
Pages (from-to)3835-3853
Number of pages19
JournalProteomics
Volume10
Issue number21
DOIs
Publication statusPublished - Nov 2010

Fingerprint

Oncogenes
Proteomics
Annexin A6
Animals
Animal Models
Breast Neoplasms
Tumors
Neoplasms
Breast
ErbB-2 Receptor
Far-Western Blotting
Proteins
Molecular Chaperones
Cell growth
Proteome
Human Mammary Glands
Immunoprecipitation
Autoantibodies
Cell Movement
Protein Isoforms

Keywords

  • Autoantibody
  • Cell biology
  • Immunoprevention
  • Mammary cancer
  • Transgenic mice
  • Vaccine

ASJC Scopus subject areas

  • Molecular Biology
  • Biochemistry

Cite this

Croci, S., Recktenwald, C. V., Lichtenfels, R., Nicoletti, G., Dressler, S. P., De Giovanni, C., ... Seliger, B. (2010). Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system. Proteomics, 10(21), 3835-3853. https://doi.org/10.1002/pmic.200900643

Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system. / Croci, Stefania; Recktenwald, Christian V.; Lichtenfels, Rudolf; Nicoletti, Giordano; Dressler, Sven P.; De Giovanni, Carla; Astolfi, Annalisa; Palladini, Arianna; Shin-Ya, Kazuo; Landuzzi, Lorena; Nanni, Patrizia; Lollini, Pier Luigi; Seliger, Barbara.

In: Proteomics, Vol. 10, No. 21, 11.2010, p. 3835-3853.

Research output: Contribution to journalArticle

Croci, S, Recktenwald, CV, Lichtenfels, R, Nicoletti, G, Dressler, SP, De Giovanni, C, Astolfi, A, Palladini, A, Shin-Ya, K, Landuzzi, L, Nanni, P, Lollini, PL & Seliger, B 2010, 'Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system', Proteomics, vol. 10, no. 21, pp. 3835-3853. https://doi.org/10.1002/pmic.200900643
Croci, Stefania ; Recktenwald, Christian V. ; Lichtenfels, Rudolf ; Nicoletti, Giordano ; Dressler, Sven P. ; De Giovanni, Carla ; Astolfi, Annalisa ; Palladini, Arianna ; Shin-Ya, Kazuo ; Landuzzi, Lorena ; Nanni, Patrizia ; Lollini, Pier Luigi ; Seliger, Barbara. / Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system. In: Proteomics. 2010 ; Vol. 10, No. 21. pp. 3835-3853.
@article{18d36d52d1e645069ae3dd660ee8894b,
title = "Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system",
abstract = "The prevention of mammary carcinoma by immunological strategies targeting the HER-2/neu receptor has proved to be effective in preclinical models. Thus, a well-characterized HER-2/neu oncogene-driven mammary carcinogenesis model was analysed by various profiling strategies following {"}triplex{"} vaccination to identify new candidate targets for breast cancer immunoprevention. 2-DE-based proteomic profiling of preneoplastic and tumour lesions versus normal and aged mammary tissue demonstrated that tumour progression was associated with an up-regulation of molecular chaperones including glucose-regulated protein (GRP)78 and of proteins favouring cell motility, which was in line with the corresponding transcriptomic profiling data. Furthermore, PROTEOMEX analyses suggested that naturally induced autoantibody responses occur during early phases of mammary cancer progression. Most of the cancer progression-induced antibodies targeted proteins of normal and preneoplastic mammary glands. However, three proteins were only recognized by sera obtained from vaccinated mice, including 2 isoforms of annexin A6. The distinct expression patterns for annexin A6 and GRP78 during tumour progression were further verified by western blot and/or immunoprecipitation. In addition, an inhibitor-mediated blockade of GRP78 expression in a model cell line caused a reduced cell growth. Thus, the proteome-based approaches applied in the murine BALB-NeuT model might indeed provide candidates for immunoprevention strategies in breast cancer.",
keywords = "Autoantibody, Cell biology, Immunoprevention, Mammary cancer, Transgenic mice, Vaccine",
author = "Stefania Croci and Recktenwald, {Christian V.} and Rudolf Lichtenfels and Giordano Nicoletti and Dressler, {Sven P.} and {De Giovanni}, Carla and Annalisa Astolfi and Arianna Palladini and Kazuo Shin-Ya and Lorena Landuzzi and Patrizia Nanni and Lollini, {Pier Luigi} and Barbara Seliger",
year = "2010",
month = "11",
doi = "10.1002/pmic.200900643",
language = "English",
volume = "10",
pages = "3835--3853",
journal = "Proteomics",
issn = "1615-9853",
publisher = "Wiley-VCH Verlag",
number = "21",

}

TY - JOUR

T1 - Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system

AU - Croci, Stefania

AU - Recktenwald, Christian V.

AU - Lichtenfels, Rudolf

AU - Nicoletti, Giordano

AU - Dressler, Sven P.

AU - De Giovanni, Carla

AU - Astolfi, Annalisa

AU - Palladini, Arianna

AU - Shin-Ya, Kazuo

AU - Landuzzi, Lorena

AU - Nanni, Patrizia

AU - Lollini, Pier Luigi

AU - Seliger, Barbara

PY - 2010/11

Y1 - 2010/11

N2 - The prevention of mammary carcinoma by immunological strategies targeting the HER-2/neu receptor has proved to be effective in preclinical models. Thus, a well-characterized HER-2/neu oncogene-driven mammary carcinogenesis model was analysed by various profiling strategies following "triplex" vaccination to identify new candidate targets for breast cancer immunoprevention. 2-DE-based proteomic profiling of preneoplastic and tumour lesions versus normal and aged mammary tissue demonstrated that tumour progression was associated with an up-regulation of molecular chaperones including glucose-regulated protein (GRP)78 and of proteins favouring cell motility, which was in line with the corresponding transcriptomic profiling data. Furthermore, PROTEOMEX analyses suggested that naturally induced autoantibody responses occur during early phases of mammary cancer progression. Most of the cancer progression-induced antibodies targeted proteins of normal and preneoplastic mammary glands. However, three proteins were only recognized by sera obtained from vaccinated mice, including 2 isoforms of annexin A6. The distinct expression patterns for annexin A6 and GRP78 during tumour progression were further verified by western blot and/or immunoprecipitation. In addition, an inhibitor-mediated blockade of GRP78 expression in a model cell line caused a reduced cell growth. Thus, the proteome-based approaches applied in the murine BALB-NeuT model might indeed provide candidates for immunoprevention strategies in breast cancer.

AB - The prevention of mammary carcinoma by immunological strategies targeting the HER-2/neu receptor has proved to be effective in preclinical models. Thus, a well-characterized HER-2/neu oncogene-driven mammary carcinogenesis model was analysed by various profiling strategies following "triplex" vaccination to identify new candidate targets for breast cancer immunoprevention. 2-DE-based proteomic profiling of preneoplastic and tumour lesions versus normal and aged mammary tissue demonstrated that tumour progression was associated with an up-regulation of molecular chaperones including glucose-regulated protein (GRP)78 and of proteins favouring cell motility, which was in line with the corresponding transcriptomic profiling data. Furthermore, PROTEOMEX analyses suggested that naturally induced autoantibody responses occur during early phases of mammary cancer progression. Most of the cancer progression-induced antibodies targeted proteins of normal and preneoplastic mammary glands. However, three proteins were only recognized by sera obtained from vaccinated mice, including 2 isoforms of annexin A6. The distinct expression patterns for annexin A6 and GRP78 during tumour progression were further verified by western blot and/or immunoprecipitation. In addition, an inhibitor-mediated blockade of GRP78 expression in a model cell line caused a reduced cell growth. Thus, the proteome-based approaches applied in the murine BALB-NeuT model might indeed provide candidates for immunoprevention strategies in breast cancer.

KW - Autoantibody

KW - Cell biology

KW - Immunoprevention

KW - Mammary cancer

KW - Transgenic mice

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=78049381358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049381358&partnerID=8YFLogxK

U2 - 10.1002/pmic.200900643

DO - 10.1002/pmic.200900643

M3 - Article

C2 - 20957756

AN - SCOPUS:78049381358

VL - 10

SP - 3835

EP - 3853

JO - Proteomics

JF - Proteomics

SN - 1615-9853

IS - 21

ER -